Fig. 7: In vivo antitumor efficacy of pristimerin in a xenograft mouse model. | Cell Death Discovery

Fig. 7: In vivo antitumor efficacy of pristimerin in a xenograft mouse model.

From: Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo

Fig. 7

a MDA-MB-231 cells were subcutaneously injected into the nude mice. Intraperitoneal treatment of the vehicle or of 0.5 mg/kg pristimerin (n = 8) daily was administered. The tumor volume was monitored. b At the end of the experiment, the tumors were excised. Images of resected human breast tumor taken for the vehicle and pristimerin treatment groups. c The tumors were weighed. d The body weights were calculated for the vehicle and pristimerin treat mice during the experiment. e Western blot analysis was used to determine the expression of cleaved caspase-3, LC-3 II, p-JNK, and JNK from respective tumor tissue lysates. f The Trx-1 activity was assessed in tumor tissue lysates. g Nude mice were treated with pristimerin by intraperitoneal injection every day for 14 days, and blood samples were collected and measured for ALT and AST expression in the vehicle and pristimerin-treatment mice. Results from three independent experiments are presented. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control, #P < 0.05, ##P < 0.01 and ###P < 0.001 versus pristimerin treatment

Back to article page